A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age; mRNA-1647-P104

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Up to 18 years old
This study is also accepting healthy volunteers

Inclusion Criteria:

- female or male 9 to 15 years of age - in good general health - BMI requirements (study staff will review) - female participants of childbearing potential: negative pregnancy test and adequate contraception for at least 28 days prior to receiving vaccine through 3 months following vaccine administration

Exclusion Criteria:

- received, or plans to receive, any nonstudy vaccine less than 28 days prior to or after any study medication - any diagnosis or condition requiring significant changes in management or medication within the 2 months before starting the study - contact study staff for review of additional exclusion criteria

Conditions & Interventions

Interventions:
Other: Placebo, Biological: mRNA-1647
Conditions:
Children's Health, Infectious Diseases
Keywords:
CMV, cytomegalovirus, vaccine

More Information

Description: This study it to test an investigational vaccine called mRNA-1647 that is being developed for preventing cytomegalovirus (CMV) infection in people. CMV is a common virus that can spread easily through an infected person’s saliva or other body fluids such as blood, urine, and breast milk. We want see if the trial vaccine can prevent CMV infection in participants who have not been previously infected, to understand the safety (how many side effects you may have) of the trial vaccine, and to see if the trial vaccine results in participants making antibodies to CMV.
Study Contact: CMVibe UMN Study - cmvibe@umn.edu
Principal Investigator: Mark Schleiss
Phase: PHASE1
IRB Number: SITE00001871